Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing

Blood

Volumn 122, Issue 7, 2013, Pages 1256-1265

  Morin, Ryan D ^a,b   Mungall, Karen ^a   Pleasance, Erin ^a   Mungall, Andrew J ^a   Goya, Rodrigo ^a   Huff, Ryan D ^a   Scott, David W ^a   Ding, Jiarui ^c   Roth, Andrew ^c   Chiu, Readman ^a   Corbett, Richard D ^a   Chan, Fong Chun ^a   Mendez Lago, Maria ^a   Trinh, Diane L ^a,c   Bolger Munro, Madison ^a   Taylor, Greg ^a   Khodabakhshi, Alireza Hadj ^a   Ben Neriah, Susana ^a   Pon, Julia ^a   Meissner, Barbara ^a   Woolcock, Bruce ^a   Farnoud, Noushin ^a   Rogic, Sanja ^a   Lim, Emilia L ^a   Johnson, Nathalie A ^d   Shah, Sohrab ^c   Jones, Steven ^a,b   Steidl, Christian ^a,c   Holt, Robert ^a,b   Birol, Inanc ^a,c   Moore, Richard ^a   Connors, Joseph M ^a   Gascoyne, Randy D ^a,c   Marra, Marco A ^a,c   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD70 ANTIGEN; CD83 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; HISTONE H1; PROTEIN BCL 2; PROTEIN BCL 6; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y8 RECEPTOR; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MESSENGER RNA; TUMOR MARKER;

ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CLONAL VARIATION; EXON; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENE STRUCTURE; GENETIC TRANSCRIPTION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; MISSENSE MUTATION; MUTATION RATE; POINT MUTATION; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; SOMATIC MUTATION; T LYMPHOCYTE; TRANSCRIPTION INITIATION SITE; WHOLE GENOME SEQUENCING; CHEMISTRY; COPY NUMBER VARIATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENOME, HUMAN; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84886290682     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-483727     Document Type: Article

References (49)

1. Pasqualucci L, Guglielmino R, Malek S.N., et al. Aberrant Somatic Hypermutation Targets an Extensive Set of Genes in Diffuse Large B-Cell Lymphoma. ASH Annual Meeting Abstracts. 2004; 104(11): 1528-1528.
2. Morin RD, Mendez-Lago M, Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360): 298-303.
3. Pasqualucci L, Trifonov V, Fabbri G., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43(9): 830-837.
4. Lohr JG, Stojanov P, Lawrence M.S., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012; 109(10): 3879-3884.
5. Zhang J, Grubor V, Love C.L., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013; 110(4): 1398-1403.
6. Lenz G, Wright GW, Emre NCT, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008; 105(36): 13520-13525.
7. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277): 88-92.
8. Morin RD, Johnson NA, Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2): 181-185.
9. Pasqualucci L, Dominguez-Sola D, Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471(7337): 189-195.
10. Goya R, Sun MGF, Morin RD, et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics. 2010; 26(6): 730-736.
11. Ding J, Bashashati A, Roth A., et al. Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics. 2012; 28(2): 167-175.
12. Trinh DL, Scott DW, Morin R.D., et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013; 121(18): 3666-3674.
13. Li H, Handsaker B, Wysoker A., et al.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16): 2078-2079.
14. Robinson JT, Thorvaldsdóttir H, Winckler W., Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011; 29(1): 24-26.
15. Greenman C, Wooster R, Futreal P.A., Stratton MR, Easton DF. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics. 2006; 173(4): 2187-2198. (Pubitemid 44285695)
16. Birol I, Jackman SD, Nielsen C.B., et al. De novo transcriptome assembly with ABySS. Bioinformatics. 2009; 25(21): 2872-2877.
17. Bashashati A, Haffari G, Ding J., et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol. 2012; 13(12):R124.
18. Nik-Zainal S., Van Loo P, Wedge DC, et al.; Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell. 2012; 149(5): 994-1007.
19. Greenman CD, Pleasance ED, Newman S, et al. Estimation of rearrangement phylogeny for cancer genomes. Genome Res. 2012; 22(2): 346-361.
20. Jones SJ, Laskin J, Li Y.Y., et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010; 11(8):R82-R82.
21. Ha G, Roth A, Lai D., et al. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res. 2012; 22(10): 1995-2007.
22. Khodabakhshi AH, Morin RD, Fejes A.P., et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget; 2012; 3(11): 1308-1319.
23. Gonzalez-Aguilar A., Idbaih A, Boisselier B., et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012; 18(19): 5203-5211.
24. Schwartzentruber J, Korshunov A, Liu X-Y, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384): 226-231.
25. Hintzen RQ, Lens SM, Lammers K, Kuiper H., Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995; 154(6): 2612-2623.
26. Kuwano Y, Prazma CM, Yazawa N, et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol. 2007; 19(8): 977-992. (Pubitemid 47386923)
27. Cattoretti G, Mandelbaum J, Lee N., et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 2009; 69(22): 8686-8692.
28. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012; 30: 69-94.
29. Sinha RK, Park C, Hwang I-Y, Davis MD, Kehrl JH. B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis. Immunity. 2009; 30(3): 434-446.
30. Hans CP, Weisenburger DD, Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno-histochemistry using a tissue microarray. Blood. 2004; 103(1): 275-282. (Pubitemid 38029949)
31. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427): 108-112.
32. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144(1): 27-40.
33. Scott DW, Mungall KL, Ben-Neriah S, et al. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood. 2012; 119(21): 4949-4952.
34. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009; 461(7265): 809-813.
35. Ding L, Ley TJ, Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382): 506-510.
36. Green MR, Gentles AJ, Nair R.V., et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013; 121(9): 1604-1611.
37. Pleasance ED, Cheetham RK, Stephens P.J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463(7278): 191-196.
38. Clément J-F, Meloche S, Servant MJ. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 2008; 18(9): 889-899.
39. Laghi L, Bianchi P, Delconte G., et al. MSH3 protein expression and nodal status in MLH1-deficient colorectal cancers. Clin Cancer Res. 2012; 18(11): 3142-3153.
40. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science. 1990; 249(4969): 655-659. (Pubitemid 20259082)
41. Furukawa T, Kuboki Y, Tanji E., et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011; 1: 161.
42. 2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 2011; 12(7): 672-680.
43. Takuwa N, Du W, Kaneko E., Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res. 2011; 1(4): 460-481.
44. Richter J, Schlesner M, Hoffmann S., et al.; ICGC MMML-Seq Project. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012; 44(12): 1316-1320.
45. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418): 116-120.
46. Monti S, Chapuy B, Takeyama K., et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012; 22(3): 359-372.
47. Siegert JL, Rushton JJ, Sellers W.R., Kaelin WG Jr, Robbins PD. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 2000; 19(50): 5703-5711.
48. Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci USA. 2008; 105(44): 16958-16963.
49. Li H-H, Li A.G., Sheppard HM, Liu X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell. 2004; 13(6): 867-878. (Pubitemid 38438481)